arrow
C

Christian Caglevic

fundacion arturo lopez perez oeci cancer center- centro de investigacion e innovacion en cancer
H指数:27
被引数:9,322

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

1 Pembrolizumab Plus Belzutifan Versus Pembrolizumab Plus Placebo as Adjuvant Therapy for Renal Cell Carcinoma: Patient-Reported Outcomes in LITESPARK-022

1 帕博利珠单抗联合贝舒妥昔单抗与帕博利珠单抗联合安慰剂作为肾细胞癌辅助治疗:LITESPARK-022研究中的患者报告结局

2026-09-020
OAAI
Pharmacokinetics and Bioavailability of Pembrolizumab With Berahyaluronidase Alfa for Subcutaneous Administration in Participants With Advanced or Metastatic Solid Tumors: The Phase 1 Study 3475A-C18

帕博利珠单抗联合重组人透明质酸酶α皮下给药的药代动力学与生物利用度研究:晚期或转移性实体瘤患者I期研究3475A-C18

2025-08-090
PREAI
The Armed Conflict and the Impact on Patients With Cancer in Ukraine: Urgent Considerations
2022-08-0131
OAAI
KEYNOTE-042 5-YEAR SURVIVAL UPDATE: PEMBROLIZUMAB VERSUS CHEMOTHERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED, PD-L1POSITIVE, LOCALLY ADVANCED OR METASTATIC NON-SMALL-CELL LUNG CANCER
2021-11-108
OA
Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial

Pembrolizumab与紫杉醇治疗先前治疗的PD-L1-positive晚期胃癌或胃食管交界癌: 随机3期KEYNOTE-061试验的2年更新

2021-09-01100
OAAI
Recommendations for detection, prioritization, and treatment of thoracic oncology patients during the COVID-19 pandemic: the THOCOoP cooperative group

新型冠状病毒肺炎大流行期间胸部肿瘤患者的检测,优先排序和治疗建议: THOCOoP合作小组

2020-09-0114
OAAI
Access to innovative medicines for metastatic melanoma worldwide: Melanoma World Society and European Association of Dermato-oncology survey in 34 countries

全球转移性黑色素瘤创新药物的获取: 黑色素瘤世界协会和欧洲皮肤肿瘤学协会在34个国家的调查

2018-11-0147
PREAI
Outcomes by line of therapy and programmed death ligand 1 expression in patients with advanced melanoma treated with pembrolizumab or ipilimumab in KEYNOTE-006: A randomised clinical trial
2018-09-0189
OAAI